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Background: Statin has been widely used to treat hyperlipidemia because of its high
potency in decreasing cholesterol levels. The present study aimed to examine the lipid-
lowering effect of rosuvastatin and the composition, diversity and species abundance
of gut microbiome in association with rosuvastatin efficacy. Trial registration: ChiCTR-
ORC-17013212 at the First Affiliated Hospital of Dalian Medical University, November 2,
2017.
Results: Totally 64 patients with hyperlipidemia were treated with 10 mg/day of
rosuvastatin for 4–8 weeks. Blood lipid indicators triglycerides (TG), total cholesterol
(TC), high density lipoprotein (HDL), low-density lipoprotein cholesterol (LDL-C) were
measured before and after the treatment. Stool samples were collected right after the
treatment. Following total DNA extraction and PCR amplification of 16S rRNA gene,
Illumina sequencing was performed for gut microbiome identification, classification and
characterization. All the patients showed a significant blood lipid reduction after the
treatment. The patients were grouped according to parallel manner design. Group I had
33 patients whose blood lipid levels dropped to the normal levels from week 4, with
58.5% reduction in LDL-C and 26.6% reduction in TC. Group II had 31 patients whose
blood lipid levels were still above the normal levels after 8 weeks therapy, but with 41.9%
reduction in LDL-C and 31.2% reduction in TC. Based on Operational Taxonomic Unit
data, Alpha-diversity by Shannon Index was different between the two groups, and
beta-diversity by Principle Component Analysis exhibited separated patterns of the two
groups. The differences were also observed in the relative-abundance at phylum, family,
and genus levels of the two groups. Linear discriminate analysis illustrated that the
abundance of 29 taxa was higher in group I, while the abundance of other 13 taxa was
higher in group II. Phyla Firmicutes and Fusobacteria had negative correlation to LDL-C
level, but Cyanobacteria and Lentisphaerae had a positive correlation to LDL-C level.
Moreover, gender and age were also found somehow correlated to microbial community
composition.
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Conclusion: Rosuvastatin therapy had different blood lipid-lowering effect on
hyperlipidemia. The gut microbiota exhibited variation in community composition,
diversity and taxa in association to rosuvastatin hypolipidemic effect. These results
indicate that modulation of gut microflora, especially the negative/positive correlated
species might strengthen statin efficacy in statin-inadequate patients.
Keywords: gut microbiome, 16S rRNA sequencing, rosuvastatin, hyperlipidemia, hypolipidemic effect
INTRODUCTION
Hyperlipidemia, high blood cholesterol and Triglycerides, is
considered a major risk factor for coronary heart disease,
ischemic stroke, and peripheral artery disease. The causes of
hyperlipidemia can be primary such as genetic defects or
secondary such as excessive eating, high saturated fatty acid
diet, smoking, less physical activity, obesity, certain medications.
Due to the changes in lifestyle and dietary, blood lipid levels
and the incidence of cardiovascular diseases increase greatly in
Chinese people lately (Pisciotta et al., 2015). According to WHO
Representative Office in China, annual cardiovascular events are
predicted to increase by 50% between 2010 and 2030 considering
only population aging and growth in China, but by 23% in
addition when considering the tendency in blood pressure,
TC, diabetes, and active smoking etc. Overall an increase of
approximate 21.3 million cardiovascular events and 7.7 million
cardiovascular deaths pose a serious challenge to Chinese public
health-care system .
To date, statin drugs are widely used for treatment of
hyperlipidemia. The action mechanisms of statins include
reducing mevalonic acid synthesis through inhibiting HMG-CoA
reductase, elevating the plasma expression of LDL-C receptor
so as to promote LDL-C uptake, decreasing the synthesis of
hepatic VLDL-C and LDL-C, and accelerating the clearance of
plasma LDL-C. Rosuvastatin is the third-generation of statin
drugs. It acts as a synthetic HMG-CoA reductase inhibitor made
up of amino-pyrimidine derivatives. Water-soluble and lipid-
soluble rosuvastatin enters the human body without metabolism,
thus enhance its lipid-lowering activity. Moreover it reduces not
only cholesterol levels but also other lipid profiles such as TGs.
Rosuvastatin is therefore widely used in primary and secondary
prevention of coronary artery disease (Athyros et al., 2002; Zhou
and Liao, 2010; Mihaylova et al., 2012; Perk et al., 2012; Taylor
et al., 2013; Al-Mohaissen et al., 2016; Lamprecht et al., 2017;
Yeramaneni et al., 2017). However, it has been noticed since 1990s
that about 20% patients showed inadequate or resistant response
to statin therapy regardless of increasing doses (Wang, 2011;
Chan et al., 2016). The high dose of statin uses tends to induce
the adverse effects such as muscle toxicity and hepatic injury.
Abbreviations: ACE, abundance-based coverage estimators; AEs, adverse events;
ANOSIM, analysis of similarities; BPB, butyrate-producing bacteria; FDR, false
discovery rate; Fiaf, fasting-induced adipose factor; HDL, high density lipoprotein;
LDA, linear discriminate analysis; LDL-C, low-density lipoprotein cholesterol;
LefSe, linear discriminant analysis effect size; OTUs, operational taxonomic
units; PCA, principal component analysis; RC, Rhizoma Coptidis; SCFA, short-
chain fatty acid; TC, total cholesterol; TG, triglycerides; VLDL, very low density
lipoprotein; VLDL-C, very low density lipoprotein cholesterol.
Gut microflora are essential in human metabolism of dietary
components and host-generated substances, particularly lipid
metabolism. The total amount of gastrointestinal bacteria is
around 1014 of a healthy adult, more than the total number
of body cells (Simren et al., 2013), which comprise a complex
and metabolic active ecosystem (Parkes et al., 2008). The
quantity and diversity of gut microbiota affect the development
of some chronic diseases (Balsari et al., 1982; West, 2014;
Erdman, 2016; Knip and Siljander, 2016) through involving
in both nutrient and energy metabolism and host immune
defense (Heyman et al., 1989; Martin et al., 2007; Ley et al.,
2008). Recent studies reveal a close relationship between the
gut microbiota and hyperlipidemia. Hyperlipidemia patients are
often accompanied with intestinal flora disorders that might
further impair lipid metabolism. In fecal flora of hyperlipidemia
patients, Gram-negative bacillus species increase, as well as the
bacteria producing SCFAs reduced significantly (Wang et al.,
2016). Dong and coworkers reported a change in composition of
intestinal flora and its impact on lipid-lowering effect in obese
rats (Dong et al., 2016).
In order to understand the association between the statin
effect and gut microbiota as well as the potential treatment for
statin inadequate patients, the present study aimed to examine
(1) the lipid-lowering effect of rosuvastatin on hyperlipidemia,
(2) the fecal microbiota composition, diversity and abundance at
phylum, family and genus levels, and (3) gut microbiota variation
on age and gender in association to rosuvastatin effectiveness.
MATERIALS AND METHODS
Subjects and Study Design
The study was performed with the approval of the Ethics
Committee of The First Affiliated Hospital, Dalian Medical
University, China (No. YJ-KY-FB-2015-12). All study
participants provided with written informed consent before
their enrolment. We consecutively enrolled 64 subjects with
primary hyperlipidemia (55–75 years, 45 men and 19 women) at
the First Affiliated Hospital of Dalian Medical University from
December 2015 to October 2016. The diagnosis of hyperlipidemia
was based on the following inclusion criteria set by the Chinese
society of Cardiology in 2007: serum LDL-C ≥ 3.64 mmol/L,
HDL ≤ 3.64 mmol/L, TG ≥ 1.70 mmol/L, TC ≥ 5.72 mmol/L.
Patients were excluded if they had at least one of the following
conditions: (1) a history of antibiotic application (within
3 months); (2) long-term use of steroid hormone, thyroid
hormone, contraceptive drugs and drugs that affect lipid
parameters of serum; (3) active liver and kidney diseases; (4)
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uncontrolled hypothyroidism; (5) adrenocortical hyperfunction;
(6) acute and chronic disorders of the digestive system. All
patients received 10 mg/day of rosuvastatin for 4–8 weeks and
the levels of serum lipids including LDL-C, HDL, TG, and
TC were measured pre- and post-treatment using Assay Kits
(BioSino Bio-Technology & Science Inc., Beijing, China). Parallel
manner design was applied as Group I with 33 patients whose
blood lipid levels dropped to the normal levels from week 4 and
Group II with 31 patients whose blood lipid levels were still above
the normal levels after 8 weeks rosuvastatin intervention. Fresh
fecal specimens were collected from each subject with a sample
box sterilized by ethylene oxide within 30 min of defecation and
then stored at−80◦C for downstream analysis.
Isolation of Total DNA From Fecal
Samples
Genomic DNA was extracted from the fecal sample (50–100 mg)
with an E.Z.N.A. Stool DNA Kit (Omega Bio-Tek, Inc., Norcross,
GA, United States) according to the manufacturer’s protocol.
The total DNA quantitation was determined using Qubit V2.0
fluorometer (Invitrogen, Carlsbad, CA, United States) and the
quality of DNA was evaluated by agarose gel electrophoresis.
Extracted DNA samples were stored at −80◦C until further
processing.
16S rRNA Gene Sequencing
16S rRNA gene sequences were amplified from the bulk DNA
with the barcoded primers 341F (5′-CCTAYGGGRBGCASCAG-
3′) and 806R (5′-GGACTACNNGGGTATCTAAT-3′), which
covers V3–V4 regions of the 16S rRNA gene (Sundberg et al.,
2013). After an initial denaturation step at 98◦C for 1 min, PCR
amplification was carried out using 30 cycles of 98◦C for 10 s,
50◦C for 30 s and 72◦C for 30 s, and a final extension at 72◦C for
5 min. PCR reactions were performed on an ABI GeneAmp 9700
PCR system (Applied Biosystems, Foster City, CA, United States).
The 16S amplicons were purified with GeneJET PCR Purification
Kit (Thermo Fisher Scientific, Waltham, MA, United States)
and DNA library was constructed by using TruSeq DNA PCR-
Free Library Kit (Illumina Inc., San Diego, CA, United States).
The libraries were then sequenced by Hiseq sequencing System
(Illumina Inc., San Diego, CA, United States). After trimming
barcodes and primer sequences, the remaining sequential reads of
each sample were linked by FLASH V1.2.7 (Magoc and Salzberg,
2011) (Fast Length Adjustment of SHort reads1). Quality control
of the sequence data was done using the open-source software
QIIME (Caporaso et al., 2010) (Quantitative Insights Into
Microbial Ecology, version 1.7.02). The sequences were removed
according to the following criteria: read length no longer than
150 bp, average quality score less than 20 and homopolymers
longer than eight nucleotides. Sequences identified as chimeras
were filtered from further study with UCHIME3 (Edgar et al.,





Taxonomic Classification of 16S Gene
Sequences
Taxonomy-based analyses were conducted using the Ribosomal
Database Project Naive Bayes classifier (Cole et al., 2005), with
a confidence of 95%. The remaining sequences with more than
97% similarity threshold were clustered into OTUs. Each read
was classified to phylum, class, order, family, and genus with
the SILVA reference database. The relative abundance of species
was calculated by dividing the number of sequences of each
taxonomic level by the total number of sequences per sample.
Bioinformatic and Statistical Analysis
Microbiome diversity was estimated by alpha diversity
(within communities) and beta diversity (between microbial
communities) analyses. Alpha diversity evaluated species
richness with ACE index and Chao 1 index, diversity with
Shannon and Simpson indexes, and Coverage index (Human
Microbiome Project Consortium, 2012). The number of OTUs
also reflects the richness of microbiome. OTU was assigned
by 3% divergence cutoff value. Generation of rarefaction
curves and calculation of alpha diversity indices were done
with Mothur software v1.20.0 program (Schloss et al., 2009).
PCA and the ANOSIM were performed to evaluate differences
between microbial communities. The phylogenetic distance
was calculated and plotted using UniFrac distance metric
between groups. The correlation between microbiome taxa and
rosuvastatin effectiveness were assessed using LDA effect size
(LEfSe) at various taxonomic ranks (Segata et al., 2011). The
LDA score of greater than 3.0 is thought to be significant by
default. LEfSe data were analyzed using statistical software R
(version 3.2.35), Q-values were adjusted using the Benjamini–
Hochberg FDR correction. The results were shown on taxonomy
bar-chart and cladogram plots. Student’s T-test was used to
identify the differences between two groups, with P < 0.05 being
considered a significant difference. To analyze the relationships
of fecal microbiome with rosuvastatin effectiveness, Spearman
correlations were calculated pairwise and a heatmap based on
Spearman correlation coefficients was plotted (Azen and Sass,
2008). R-value of Spearman Correlation coefficient represented
the relevance of two group, r < 0 was considered as a negative
correlation, as well as r > 0 was a positive correlation. P-values
were considered significant using a FDR of 25%.
RESULTS
Efficacy of Rosuvastatin
A total of 64 patients with primary hyperlipidemia received
rosuvastatin treatment at the First Affiliated Hospital of Dalian
Medical University. The therapy was well tolerated in all the
subjects with good compliance and with no obvious drug-related
AEs during rosuvastatin administration. The lipid patterns were
without difference at baseline. The changes of serum lipids were
determined after rosuvastatin administration for 4–8 weeks. TC,
5www.r-project.org
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TG, and LDL-C reduced significantly compared to baseline, as
well as HDL elevated slightly in all subjects. According to the
degrees of lipid-lowering, subjects were classified into two parallel
groups: group I, with high efficacy of rosuvastatin treatment;
group II, with relatively low efficacy of rosuvastatin treatment.
The patients of group I achieved apparently a greater decrease in
TC and LDL-C. TC was−41.9% in group I and−26.6% in group
II, LDL-C was −58.5 and −26.6% in two groups, respectively.
However, the decline of TG level was not significant between
the two groups. A summary of serum lipids before and after
rosuvastatin treatment was presented in Table 1.
Analyses of Alpha and Beta Diversity
To compare the microbial diversity between groups I and II, the
extracted genomic DNA from stool samples were subjected to 16S
rRNA gene sequencing. Rarefaction curve and rank abundance
curve were plotted to analyze the ecological parameters such
as diversity or richness which reflected the depth and coverage
of sequencing. As seen in Figure 1A, a rarefaction curve of
the observed species number versus sequences in each sample
showed the efficiency of the sequencing and sufficient sampling
depth, as well as high similarity among group members. In
Figure 1B, the line slopes of rank abundance curve indicated
species (OTU) evenness, line lengths reflected OTU richness,
and the long tail represented less abundant taxa. Based on
the OTU data, alpha diversity measurement was shown on
several indices. The ACE index and Chao 1 index were used
to explore the total number of species in an ecosystem, and
were calculated through two different formulas. The Shannon
index and Simpson index reflected the heterogeneity in the
microbiome. The results revealed that richness indices, ACE and
Chao 1, were not different comparing the samples from the two
groups. However, a significant difference in alpha diversity was
spotted by Shannon index (P < 0.05) of the two groups’ gut
microbiome. Shannon indexes of groups I and II were 6.240.54
and 5.810.49, respectively, suggesting that the complexity of
fecal microbiome could be positively correlated with rosuvastatin
effectiveness. Furthermore, Coverage index of two groups were
all more than 99.8%, suggesting a high sequencing coverage of
samples in the trial.
We next performed beta diversity analysis to compare the
similarity among gut microbiome of the two groups (Figure 2).
PCA plot revealed that the gut microbiome of different groups
was well separated from each other, microbial community of
group I clustered in green circle, and those of group II gathered
in blue circle. However, the community of male subjects was not
readily differentiated from females within the group.
Comparison of Gut Microbiome at
Phylum, Family, and Genus Levels
The relative abundances of overall microbiome between the
groups differed at the phylum, family and genus levels, but most
of these differences were without statistically significant. At the
phylum level, sequences from the Firmicutes and Bacteroidetes
phyla were most abundant in both the groups, accounting for
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FIGURE 1 | (A) Rarefaction curve for the number of operational taxonomic units (OTUs) observed in individual sample against sequences number. (B) Rank
abundance curve. The horizontal axis shows the OTU abundance in rank order; the vertical axis shows the relative abundance of sequences on a logarithmic scale.
FIGURE 2 | Beta diversity assessment of gut microbiome. Principles Component Analysis (PCA) was used and a scatterplot was generated to determine the
phylogenetic distances between bacterial communities. The axes indicate the percentages of variation in the data for the bacterial communities. Dot symbols in
different representing color that cluster together are circled in red, green, dark blue, and light blue, respectively.
and 44.75% in group II. Proteobacteria, Actinobacteria and
Verrucomicrobia together comprised 6.69% in group I and
19.7% in group II. The relative abundance of Firmicutes,
Verrucomicrobia, Tenericutes, and Fusobacteria were
significantly increased in group I compared to those of group
II, whereas group II exhibited a significantly higher bacterial
abundance of Bacteroidetes, Actinobacteria, Cyanobacteria, and
Lentisphaerae compared to group I (Figure 3A).
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FIGURE 3 | Relative abundance of gut microbiome. Gut microflora were profiled with the mothur pipeline. Phylum (A), family (B), and genus (C) level taxonomy are
presented as percentage of total sequences. Different colored bars indicate different gut microbial taxa.
At the family level, the samples of group I were dominated
by four families: Ruminococcaceae (20.61%), Lachnospiraceae
(17.27%), Bacteroidaceae (16.89%), and Prevotellaceae (16.73%),
but in group II were Bacteroidaceae (21.33%), Prevotellaceae
(18.19%), Ruminococcacea (17.04%), and Lachnospiraceae
(14.69%). Compared with group II, reads of group I showed
obviously lower relative abundances of Bacteroidaceae,
Prevotellaceae, Pseudomonadaceae, Rikenellaceae and higher
relative abundances of Ruminococcaceae, Lachnospiraceae,
Veillonellaceae, Christensenellaceae, Lactobacillaceae,
Verrucomicrobiaceae, Coriobacteriaceae, and Clostridiaceae_1
(Figure 3B).
Constitutionals bacteria at genus level revealed that
Bacteroides (16.93%), Prevotella_9 (15.07%), Dialister
(6.70%), Pseudobutyrivibrio (3.98%), Faecalibacterium (3.32%),
Ruminococcaceae_UCG-002 (2.66%), Ruminococcaceae_UCG-
014 (2.64%), and Ruminococcus_2 (2.12%) were the dominant
in group I, whereas the top genera in group II were, in
turn, Bacteroides (21.35%), Prevotella_9 (16.53%), Dialister
(4.42%), Pseudobutyrivibrio (3.12%), Faecalibacterium
(2.99%), Bifidobacterium (2.59%), Parabacteroides (2.40%),
and Escherichia–Shigella (2.32%). Relative abundances at genus
level differed apparently between two groups. Several genera
of group I were significantly decreased than those in group
II, including Bacteroides, Parabacteroides, and Veillonella. On
contrast, 16 genera were elevated in group I, indicating there was
a relationship between different microbiome compositions of gut
microbiota and therapeutic effects of rosuvastatin (Figure 3C).
Composition and abundance of the gut microbiome were
analyzed between the groups based on gender and age. The
females of group I showed higher relative abundance of
Firmicutes, Tenericutes (phylum level), and Ruminococcaceae,
Lachnospiraceae, Coriobacteriaceae, and Alcaligenaceae (family
level) compared to those of group II. On the other hand, the males
of group I exhibited increased OTUs of Firmicutes, Tenericutes,
Clostridiaceae_1, and declined OTUs of Bacteroidaceae
compared to those of group II (Table 2). We also observed that
distribution of gut microbiome was different on age. Relative
abundance of Firmicutes, Euryarchaeota, Lachnospiraceae,
Erysipelotrichaceae, Desulfovibrionaceae, Methanobacteriaceae,
and Clostridiales_vadinBB60_group were higher in subjects aged
from 55 to 65 of group I than those of group II, while lower
abundance of Bacteroidetes, Actinobacteria, and Cyanobacteria
were found in this subject community than those in group II.
Patients aged 65–75 years of group I have significantly more
abundant reads of Fusobacteria and notable lower OTUs of
Bacteroidaceae and Peptostreptococcaceae as compared to those
of group II. These data showed the distribution profiles of gut
microbiome in rosuvastatin-treated patients with different age
and clinical outcomes (Table 3).
Variation Analysis of Gut Microbiome
Associated With Rosuvastatin Treatment
To further assess the correlation between gut microbial taxa,
rosuvastatin effect and age, LDA coupled with effect size
measurements (LEfSe) was applied to identify the differentially
abundant OTUs between group I and II. A total of 42 taxa
manifested a significant difference in their abundance between
the two groups (LDA score > 3.0). 29 microbial taxa were
enriched in group I compared to group II, including 1 bacterial
phylum, 3 classes, 3 order, 7 families, 12 genera, and 3 species.
Group II was characterized by higher abundance of other
13 discriminatory taxa, including 1 phylum, 1 family, 3
genera, and 8 species. These taxa were depicted in Figure 4.
Spearman’s rank correlation method was used for analyzed the
associations of variation of fecal microbiome with serum lipids
and age (Figure 5). Among differentially abundant bacterial
phyla, Firmicutes or Fusobacteria were correlated negatively
with LDL-C (P < 0.05). The positive correlation were found
between LDL-C and Cyanobacteria and Lentisphaerae, as
well as between the age and Proteobacteria and Synergistetes
(P < 0.05). At the family level, TG and LDL-C were positively
correlated with Bacteroidaceae or Acidaminococcaceae
(P < 0.05) and negatively correlated with Lachnospiraceae,
Ruminococcaceae, Erysipelotrichaceae, Coriobacteriaceae,
Clostridiaceae_1, Alcaligenaceae, Peptostreptococcaceae,
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TABLE 2 | Relative abundance of gut microbiome taxa in according to gender and
rosuvastatin effectiveness.
Female Male
Group I Group II Group I Group II
Firmicutes 54.50 41.91∗ 54.71 46.61∗
Bacteroidetes 38.39 46.00 38.47 44.28
Actinobacteria 2.10 5.21 1.52 2.11
Proteobacteria 4.66 6.19 4.91 6.72
Verrucomicrobia 0.10 0.15 0.20 0.12
Euryarchaeota 0.08 0.13 0.03 0.05
Synergistetes 0.03 0.12 0.02 0.02
Tenericutes 0.11 0.05∗ 0.09 0.07∗
Prevotellaceae 16.62 20.50 16.81 17.26
Veillonellaceae 8.90 8.24 9.49 7.39
Bacteroidaceae 16.62 20.32 17.06 21.77∗
Bifidobacteriaceae 1.20 4.99 0.75 1.60
Ruminococcaceae 21.46 14.49∗ 20.41 18.18
Lachnospiraceae 17.49 13.79∗ 17.08 15.02
Enterobacteriaceae 2.66 5.04 2.78 4.64
Porphyromonadaceae 2.50 2.97 2.71 2.81
Christensenellaceae 1.28 1.29 1.53 0.90
Pasteurellaceae 0.43 0.34 0.75 0.42
Erysipelotrichaceae 0.55 0.34 0.79 0.32
Rikenellaceae 1.91 1.92 1.66 1.81
Bacteroidales_S24-7_group 0.72 0.23 0.22 0.61
Streptococcaceae 0.67 0.72 0.84 0.93
Coriobacteriaceae 0.87 0.21∗ 0.73 0.48
Lachnospiraceae 1.67 1.15 1.62 1.72
Verrucomicrobiaceae 0.10 0.20 0.12 0.15
Clostridiaceae_1 0.52 0.80 0.44 0.35∗
Desulfovibrionaceae 0.66 0.55 0.71 0.35
Alcaligenaceae 0.72 0.67 0.79 0.37
∗Significant difference between the two groups, P < 0.05.
Moraxellaceae, Actinomycetaceae, or Fusobacteriaceae
(P < 0.05). Moreover, the age was positively associated with
Lactobacillaceae, Christensenellaceae, or Synergistaceae, and
negatively associated with Bacteroidales_S24.7_group (P < 0.05).
DISCUSSION
The present study explored the effects of rosuvastatin lowering
lipid levels in the hyperlipidemia patients. After 4–8 weeks
therapy, different therapeutic efficacy was observed in the
participants. The patients were then divided into two parallel
groups, group I reached an optimal levels of TC, TG, and LDL-C
following rosuvastatin treatment, group II also achieved a lipid-
lowering effect but without reaching the normal. Rosuvastatin
is an effective lipid-lowering drug, which is commonly used for
the treatment of hyperlipidemia on the doses of 10 mg per day
in China (Ding et al., 2015). However, although the efficacy
of rosuvastatin having been well established, many patients
did not achieve ideal effects. Karlson et al. (2016) assessed
mean percentage change in LDL-C among 38,052 subjects with
TABLE 3 | Relative abundance of gut microbiome taxa in according to age and
rosuvastatin effectiveness.
55–65 years 65–75 years
Group I Group II Group I Group II
Firmicutes 0.5665 0.4491∗ 0.5193 0.4570
Bacteroidetes 0.3716 0.4691∗ 0.4020 0.4183
Actinobacteria 0.0166 0.0257∗ 0.0173 0.0362
Proteobacteria 0.0428 0.0538 0.0560 0.0820
Verrucomicrobia 0.0006 0.0003 0.0032 0.0026
Cyanobacteria 0.0000 0.0011∗ 0.0001 0.0001
Euryarchaeota 0.0004 0.0000∗ 0.0005 0.0017
Prevotellaceae 0.1543 0.2147 0.1855 0.1367
Veillonellaceae 0.1141 0.0848 0.0647 0.0646
Bacteroidaceae 0.1756 0.2078 0.1608 0.2213∗
Bifidobacteriaceae 0.0076 0.0225 0.0105 0.0305
Ruminococcaceae 0.1995 0.1608 0.2178 0.1853
Lachnospiraceae 0.1781 0.1488∗ 0.1639 0.1435
Enterobacteriaceae 0.0220 0.0352 0.0348 0.0648
Porphyromonadaceae 0.0217 0.0256 0.0328 0.0327
Christensenellaceae 0.0123 0.0065 0.0176 0.0152
Erysipelotrichaceae 0.0090 0.0034∗ 0.0047 0.0032∗
Rikenellaceae 0.0142 0.0148 0.0216 0.0235
Bacteroidales_S24_7_group 0.0056 0.0061 0.0010 0.0035
Streptococcaceae 0.0062 0.0079 0.0101 0.0097
Lachnospiraceae_1 0.0085 0.0029∗ 0.0065 0.0054
Verrucomicrobiaceae 0.0170 0.0164 0.0154 0.0144
Clostridiaceae_1 0.0006 0.0003 0.0032 0.0026
Desulfovibrionaceae 0.0078 0.0047∗ 0.0062 0.0033
Alcaligenaceae 0.0050 0.0061 0.0069 0.0060∗
Acidaminococcaceae 0.0061 0.0064 0.0079 0.0071
Peptostreptococcaceae 0.0074 0.0064 0.0046 0.0073∗
Methanobacteriaceae 0.0091 0.0046∗ 0.0075 0.0040∗
Synergistaceae 0.0004 0.0000∗ 0.0005 0.0017
Bacillaceae 0.0002 0.0001 0.0002 0.0001∗
Elusimicrobiaceae 0.0007 0.0004∗ 0.0006 0.0005
Clostridiales_vadinBB60_group 0.0003 0.0001∗ 0.0003 0.0003
∗Significant difference between the two groups, P < 0.05.
rosuvastatin oral tablet 5–40 mg daily. From the results with
VOYAGER meta-analysis they observed that rosuvastatin 5 mg
decreased LDL-C by 39% and non-HDL-C by 35%, while
rosuvastatin 40 mg reduced LDL-C by 55% and non-HDL-C by
50% in patients with hyperlipidemia. Anagnostis et al. (2014)
reported that 12-week-treatment period of rosuvastatin with
the doses of 10 mg daily led to a 49.4% reduction in LDL-C,
a 37% decrease in TC and a 27.4% decline in TG in non-
diabetic patients with dyslipidemia. These findings demonstrate
that increasing the dose of rosuvastatin and prolonging the time
of drug administration lead only to a limited reduction in the
serum lipids levels. Our results were in agreement with these
findings reported in the literature.
The human gastrointestinal microbiota act as not only an
important barrier to aggressive agents but also as modulator
in maintaining symbiotic homeostasis and normal physiology
(Robles-Alonso and Guarner, 2013; Goulet, 2015). In recent
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FIGURE 4 | Distribution of microbiome was compared between two groups by using linear discriminant analysis (LDA) effect size (LEfSe). (A) Histogram of the LDA
scores reveals the most differentially abundant taxa in two groups. The taxa listed in red represent group I and green describe group II. (B) The cladogram shows the
significantly overrepresented bacterial taxa in group I (red area) and group II (green area).
FIGURE 5 | Gut microbiota according to serum lipid level and age. Heatmaps of Spearman correlations display the relationships between bacterial phyla (A), or
bacterial family (B) and blood lipids or age. Gut microbiota according to serum lipid level and age.
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years, a growing body of literature uncover that imbalance
of gut microbiota are closely related to the occurrence and
development of a number of diseases, including obesity,
diabetes, cardiovascular disease, allergies, cancer, and so on
(Ley et al., 2006). Due to the development of 16S rRNA
sequencing technologies, variations of human gut microbiome
that associate with dyslipidemia have been well documented
by researchers. Fu et al. (2015) analyzed the relevance between
the human intestinal bacteria taxa and blood lipid levels in
893 subjects. They found 34 bacterial taxa were significantly
correlated with blood lipids levels, accounting for 6% of
the variance in TC, and 4% in HDL, independent of other
influence factors (Fu et al., 2015). A study investigating anti-
hyperlipidemia of RC alkaloids revealed that RC alkaloids
were able to change the composition of gut microbiota and
restore the balance of microflora, hence leading to a lipid-
lowering effect (He et al., 2016). These findings indicate that
gut microbiota may play crucial role in etiology of dyslipidemia.
The underlying mechanisms of gut microflora affects blood
lipid levels remain unclear. It has been addressed that gut
bacteria generate SCFAs which can modulate hepatic and/or
systemic lipid and glucose metabolism via the activation of
nuclear or G protein-coupled receptors (GPCRs). As well, gut
microflora can modulate the metabolism of bile acids that have
been implicated in the regulation of lipid, glucose, and energy
metabolism.
High-throughput DNA sequencing of 16S rRNA genes
isolated from stool specimens was used to produce large numbers
of valid reads for further microbiome analysis in this study.
We showed that the compositions of gut microbiota were
different between subjects with hyperlipidemia who displayed
optimal (group I) or suboptimal (group II) clinical outcomes
following rosuvastatin intervention. Alpha diversity analysis
demonstrated a higher complexity of fecal microbiome than that
of group II. In particular, we identified that higher abundances
of phylum of Firmicutes, BPB families of Ruminococcaceae,
Lachnospiraceae, Clostridiaceae-1, and lower abundances of
phylum of Bacteroidetes were associated with an optimal
therapeutic effect of rosuvastatin. Firmicutes participate in
the metabolic process of phenolic compounds, which act as
antidiabetic and anti-obesity agents (Selma et al., 2009; Eid
et al., 2017). Thus this bacterial phylum was indicated a
potential role in the maintenance of normal blood lipids.
BPB are located in the colon and distal small intestine,
which can ferment dietary fiber into a SCFAs named butyrate.
Decreased numbers of BPB has been involved in a number
of disorders such as fatty liver disease, inflammatory bowel
diseases, diabetes, and so on (Willing et al., 2010; Qin et al.,
2012; Endo et al., 2013). Weng et al. (2015) revealed that
butyrate-producing probiotics along with fiber administration
reduced adipose tissue mass and serum TG level in mice.
This finding indicated that BPB may act as a new therapeutic
target against hyperlipidemia and obesity. Lu et al. (2017)
observed an elevated ratio of Firmicutes to Bacteroidetes and
decreased abundance of probiotics in mice fed a high-sugar-high-
fat diet. We found group I exhibited an increased abundances
of probiotics such as Lactobacillaceae and Bifidobacteriaceae
and achieved higher effectiveness of rosuvastatin treatment.
Researchers have explored the therapeutic potential and the
underlying mechanisms of probiotics for dyslipidemia in
recent years. For example, administration of Lactobacillus in
rats fed with a high-lipid diet contributed to a significant
reduction in serum TC, TG, and LDL, and significantly
increased HDL (Wang et al., 2012). Prebiotic feeding up-
regulated the concentrations of plasma gut peptide (glucagon-
like peptide 1 and peptide YY), leading to alterations in
appetite sensation and the lowered hunger ratings in healthy
subjects (Cani et al., 2009). In another report, two probiotic
strains, Lactobacillus plantarum KY1032 and L. curvatus HY7601,
were shown to improve the hepatic mRNA expression of
PPARα, bile acid receptor, and plasma apolipoprotein A–V
in hypertriglyceridemic rats, thus exerting lipid-lowering effect
(Choi et al., 2016).
Opposite to the role of probiotics in maintaining lipid
homeostasis, certain types of bacteria inhabiting the intestines
had the potential to induce fat accumulation and obesity, this
could be confirmed by the work from Bäckhed F’s team. They
compared germ-free and colonized mice supplied with high-fat
and high-sugar diet, and found germ-free animals were protected
from the obesity by elevating Fiaf and enhancing the activity
of phosphorylated AMP-activated protein kinase in muscle and
liver (Backhed et al., 2007). High-fat diet feeding was involved
in changed compositions of gut microbes and increased plasma
lipopolysaccharide (endotoxin of Gram-negative bacteria)
levels (Cani and Delzenne, 2009). Bacterial endotoxin has been
reported to cause adipose tissue formation, systemic and local
inflammatory and metabolic disorders, which were defined
“metabolic endotoxemia” (Boutagy et al., 2016). Our results
noticed a higher richness of Actinobacteria, Lentisphaerae,
Bacteroidaceae, Prevotellaceae, Pseudomonadaceae,
Streptococcaceae, Acidaminococcaceae, Enterobacteriaceae,
Citrobacter, Veillonella, and Escherichia_Shigella in group
II, most of these bacteria belong to endotoxin-producing
microbes. Their high levels may explain partially the reason
why rosuvastatin was not that effective in subject communities
from group II. Generally, how the gut microflora impact on the
metabolism and pharmacokinetics of statins is unknown. This
might involve the microbiota together with the host cells to
maintain intestinal homeostasis, to change statin-metabolizing
enzymes and transporters and to modulate the activity of drug
receptors.
In addition, we did not observe significant difference in
microbial diversity between two groups. However, the women
cohort in group I showed higher richness of Firmicutes,
Ruminococcaceae, Lachnospiraceae, Peptostreptococcaceae,
Family_XIII bacteria, Defluviitaleaceae bacteria and lactobacillus,
as well as lower abundance of Saccharibacteria, Bacteroidaceae,
Prevotellaceae, and Enterobacteriaceae as compared to female
in group II. For male subjects in group I, markedly elevation in
bacterial phylum of Firmicues, families of Peptostreptococcaceae
and Defluviitaleaceae was observed in comparison to those in
group II. The data suggested that gender should be considered
as an influence factor together with gut microbiota compositions
in rosuvastatin treatment. Comparison between subjects ranging
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from 55–65 to 66–75 in two groups revealed that distribution
of BPB was different based on age. Age-related variation
of the microbiota occurs as an ecological succession under
the multiple perturbations associated with the conditions as
chronic gastrointestinal diseases, metabolic disorders antibiotic
use (Lozupone et al., 2012). Our age associated species
Lactobacillaceae, Christensenellaceae, or Synergistaceae did not
apply to the usual situation. However, the gut flora of individual
subjects may display little divergence with small age difference.
We also observed that the association was present between
rosuvastatin efficiency and the microbial diversity of human
gut. As the TG and LDL-C levels changed, the diversity of
the composition of gut microbiome was spotted, but not the
richness. Overall, the patient gut microbiota exhibited variation
in community diversity and taxon abundance in association
to rosuvastatin hypolipidemic effect. These results indicate that
gut microbiota have potency in influencing statin treatment to
patients with dyslipidemia; the modulation of gut microflora,
especially statin effectiveness correlated species, might provide
a management for treating statin-inadequate patients. 16S
rRNA sequencing technique gives a lot of information on the
abundance and diversity of microflora. There is scarce knowledge
of their functions and underlying mechanisms involved in
aberrant blood lipids, which we hope learn more in the
future.
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